Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
IPO Date: March 4, 1994
Sector: Healthcare
Industry: Biotech
Market Cap: $1.82B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.21 | 3.06%
Avg Daily Range (30 D): $0.17 | 1.72%
Avg Daily Range (90 D): $0.20 | 2.26%
Institutional Daily Volume
Avg Daily Volume: 1.52M
Avg Daily Volume (30 D): 2.73M
Avg Daily Volume (90 D): 3.53M
Trade Size
Avg Trade Size (Sh.): 178
Avg Trade Size (Sh.) (30 D): 113
Avg Trade Size (Sh.) (90 D): 130
Institutional Trades
Total Inst.Trades: 3,684
Avg Inst. Trade: $2.26M
Avg Inst. Trade (30 D): $3.38M
Avg Inst. Trade (90 D): $3.29M
Avg Inst. Trade Volume: .27M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.13M
Avg Closing Trade (30 D): $4.54M
Avg Closing Trade (90 D): $4.12M
Avg Closing Volume: 378.43K
   
News
Jul 15, 2025 @ 2:00 PM
AscellaHealth’s Patient-Focused Approach is...
Source: Bill Oldham
Jul 7, 2025 @ 11:00 AM
BioCryst Appoints Babar Ghias Chief Financial Offi...
Source: Babar Ghias
Jul 3, 2025 @ 11:00 AM
BioCryst Reports Inducement Grants Under Nasdaq Li...
Source: John Bluth
Jun 27, 2025 @ 11:00 AM
BioCryst Announces Sale of European ORLADEYO® (...
Source: Globe Newswire
Jun 27, 2025 @ 11:00 AM
BioCryst Announces Sale of European ORLADEYO® (...
Source: Biocryst Pharmaceuticals
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-.26 $ $-.13
Diluted EPS $-.26 $ $-.13
Revenue $ 503.49M $ 145.53M $ 131.53M
Gross Profit $ 487.91M $ 140.97M $ 125.44M
Net Income / Loss $ -53.47M $ .03M $ -26.8M
Operating Income / Loss $ 33.17M $ 21.23M $ -4.51M
Cost of Revenue $ 15.57M $ 4.57M $ 6.09M
Net Cash Flow $ 20.75M $ .56M $ 7.26M
PE Ratio